Bixiye
QP26-25 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective May 1, 2025
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 421 - 430 ee natiijooyinka 3167
Bixiye
QP25-25 MHCP Pharmacy Benefit Exclusion for Datroway®, Frindovyx™, Kebilidi™ and Niktimvo™
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Bixiye
QP24-25 Commercial Pharmacy Benefit Exclusion for Octreotide Kit, Sandostatin® Kit LAR, and Signifor® LAR injection
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Bixiye
QP23-25 Commercial Pharmacy Benefit Exclusion for Kebilidi™, Niktimvo™, Steqeyma® and Yesintek™
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Bixiye
QP22-25 Provider Press: Q1 2025
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Bixiye
QP29-25 Denials for Charges Denied based on Medicare NCD and LCD Policies
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Bixiye
QP28-25 REMINDER: Process Update for Post-Acute Care Authorizations managed by eviCore Healthcare
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025
Bixiye
QP21-25 Appropriate Use of Modifier -25
Taariikhda uu dhaqangalayo Barnaamijka: Mar 12, 2025